GlobeNewswire by notified

Basilea announces sale of preclinical oncology program to Nodus Oncology

Share
  • Sale of Basilea’s novel PARG inhibitor discovery program
  • Upfront and milestone payments of up to CHF 242 million and approximately 5% participation in net sales
  • Important step in implementing Basilea’s strategic refocus on anti-infectives

Basel/Allschwil, Switzerland, September 08, 2022

Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement with Nodus Oncology (“Nodus”) for Basilea’s novel poly(ADP-ribose) glycohydrolase (PARG) inhibitor discovery program. PARG is a key enzyme in the repair of DNA damage and essential for tumor cells to grow. Nodus is a UK-based company developing first and best-in-class molecules inhibiting novel DNA damage response (DDR) targets. It will partner with the Lead Discovery Center GmbH (LDC) in Germany to continue the development of this program.

Adesh Kaul, Chief Financial Officer of Basilea, said: “We are happy to have found a specialized oncology partner with significant expertise in the DNA damage response space. The structure of the transaction ensures that Basilea continues to participate in the long-term value creation potential of this exciting program. We also continue our ongoing partnering discussions for BAL0891 and our second pre-clinical program, for which we aim to complete transactions before the end of 2022.”

Ian Waddell, Chief Executive Officer of Nodus Oncology, said: “Nodus’ acquisition of Basilea’s PARG inhibitor program demonstrates our ongoing commitment to developing, and bringing to patients, drugs addressing next generation DDR targets. We are excited to expand our portfolio and we look forward to working with LDC to advance this program.”

Under the terms of the agreement, Basilea will receive upfront and near-term research milestone payments of CHF 1.0 million. Basilea is also eligible to receive further payments of up to CHF 241 million upon the achievement of predefined development, regulatory and sales milestones, in addition to receive approximately 5% of net sales.

In February this year Basilea announced its intention to focus on becoming a leading anti-infectives company and therefore to separate its oncology assets. Basilea has already made significant progress in the implementation of the new strategy and expects no material expenses related to oncology activities beyond 2022. Basilea is on track to achieve sustainable profitability from 2023.

About Nodus Oncology

Nodus Oncology is a biotech company developing first and best in class molecules focused on the DNA damage response (DDR) in patient sub-groups where molecular vulnerabilities exist. Founded by Cumulus Oncology, which contributes capital and oncology discovery and development expertise to the creation of new biotech companies, Nodus has received seed investment from both Cumulus Oncology and additional investors. Further information at: www.nodusoncology.com

About LDC

Lead Discovery Center GmbH (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. The LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in in vivo models as well as candidate nomination. In close collaboration with high-profile partners from research and industry, the LDC is building a strong and growing portfolio of small molecule and antibody leads with exceptional medical and commercial potential. The LDC sustains a long-term partnership with the Max Planck Society, KHAN-I GmbH & Co. KG and has formed alliances with AstraZeneca, Apeiron, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient, Jemincare, Novo Nordisk and Cumulus Oncology. In addition, LDC also works with leading translational drug discovery centers and with various investors to provide its assets for company creation. Further information at: www.lead-discovery.de.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. In addition, we have several preclinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica International Ltd, Allschwil
Hegenheimermattweg 167b
4123 Allschwil
Switzerland
Phone+41 61 606 1102
E-mailmedia_relations@basilea.com
investor_relations@basilea.com

This press release can be downloaded from www.basilea.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Inbjudan till HMS Networks telefonkonferens för det tredje kvartalet 202229.9.2022 11:30:00 CEST | Pressemelding

HMS Networks AB (publ) offentliggör sin rapport för det tredje kvartalet 2022 onsdagen den 19 oktober 2022 kl. 07.30. Samma dag kl. 09.00 arrangeras en telefonkonferens för press och aktiemarknad, där VD och koncernchef Staffan Dahlström samt finanschef Joakim Nideborn presenterar rapporten. Presentationen hålls på engelska och följs direkt via telefon eller via internet. De bilder som används under presentationen kommer att finnas tillgängliga på HMS webbplats före telefonkonferensen. För att delta i telefonkonferensen, ring in eller följ webbpresentationen via länken nedan. SE: +46 8 505 583 50 UK: +44 33 3300 9034 US: +1 646 722 4904 Länk till webbsändningen Presentation och inspelning av telefonkonferensen kommer sedan att finnas tillgängligt på HMS webbsida. https://www.hms-networks.com/sv/aktieagare För mer information, kontakta: Staffan Dahlström, VD HMS, +46 (0)35 17 29 01 Joakim Nideborn, Finanschef HMS, +46 (0)35 710 6983 HMS Networks AB (publ) är en marknadsledande leverantö

Invitation to HMS Networks’ third quarter 2022 conference call29.9.2022 11:30:00 CEST | Press release

HMS Networks AB (publ) will release its third quarter report 2022 on Wednesday October 19, 2022, at 07.30 CET. On the same day, at 09.00 CET, a conference call will be held for press and analysts, where President and CEO Staffan Dahlström and CFO Joakim Nideborn present the report. The presentation will be held in English and is followed live by telephone or the internet. Slides used in the presentation will be made available on HMS’ website prior to the telephone conference. To participate in the telephone conference, please call or follow the online presentation via the link below. SE: +46 8 505 583 50 UK: +44 33 3300 9034 US: +1 646 722 4904 Link to webcast The presentation and recording of the telephone conference will be available on HMS’ website after the call. https://www.hms-networks.com/ir For more information, please contact: Staffan Dahlström, CEO HMS, +46 (0)35 17 29 01 Joakim Nideborn, CFO HMS, +46 (0)35 710 6983 HMS Networks AB (publ) is a market-leading provider of solut

Eidosmedia partners with Sophi.io on AI-powered print automation29.9.2022 10:00:00 CEST | Press release

The partnership integrates Sophi.io’s AI technology into Eidosmedia’s editorial platform, bringing seamless ML-powered print laydown automation to Eidosmedia customers TORONTO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Eidosmedia, a developer of digital publishing solutions for leading news-media groups worldwide, has partnered with Sophi.io, an AI-powered automation, optimization and prediction platform developed by The Globe and Mail, to bring seamless print laydown automation to Eidosmedia customers. The solution brings the entire print page layout process down from hours to just minutes, without the use of templates. Publishers can dramatically improve productivity and cut costs, all within the Méthode platform they currently use. “The complexity of print page layouts has until now defied the easy automation that speeds the publishing of online formats,” said Marco Cetola, Eidosmedia Sales and Partner Program Director. “For our customers, especially large regional groups and national titl

Hypefactors project backed by Innovation Fund Denmark29.9.2022 09:54:19 CEST | Press release

Copenhagen, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Announcement no. 10-2022 Inside Information It is announced that Innovation Fund Denmark, from its Innobooster program, has granted Hypefactors DKK 988,575 to support development of the project 'New Print PDF Processing Program', in where we will develop and roll-out an advanced automated solution for processing of printed news (from newspapers and magazines). In the project, we aim to apply recent scientific breakthroughs in computational linguistics (NLP) combined with AI-techniques beyond machine learning: Automated reasoning engine and probabilistic programming. The 'New Print PDF Processing Program' will enable us to deliver a magnitude larger print coverage than any competitor​ and to​ deliver a superior solution to large enterprises with cross-border media presence. The project will kick off in October 2022 and is expected to be finalized within a period of 10 months. CEO Casper Janns: “Our dedicated ambition is to develop and deliv

Preliminary results of the recommended voluntary exchange offer for all shares in Magseis Fairfield ASA29.9.2022 08:30:00 CEST | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, INTO OR WITHIN AUSTRALIA, CANADA, HONG KONG, JAPAN, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL Oslo, Norway (29 September 2022) - Reference is made to the stock exchange announcement on 29 June 2022 regarding the recommended voluntary exchange offer (the "Offer") by TGS ASA ("TGS" or the "Offeror", OSE: TGS) to acquire all shares in Magseis Fairfield ASA ("Magseis Fairfield" OSE: MSEIS) and to the stock exchange announcement on 24 August 2022 regarding the formal launch of the Offer. Reference is also made to the offer document for the Offer dated 24 August 2022 (the "Offer Document"), and to the stock exchange announcements on 21 September 2022 regarding the extension of the offer period until 28 September 2022, on 22 September 2022 regarding the update on acceptances, and on 23 September 2022 regarding amendment of the minimu